Novelion Therapeutics Inc (NASDAQ:NVLN) (TSE:QLT) was the recipient of a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 131,100 shares, an increase of 8.2% from the May 15th total of 121,200 shares. Currently, 0.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 127,900 shares, the short-interest ratio is presently 1.0 days.
NASDAQ NVLN traded up $0.03 on Friday, hitting $0.69. 36,788 shares of the stock were exchanged, compared to its average volume of 37,121. The business has a fifty day moving average price of $0.81. Novelion Therapeutics has a 52-week low of $0.61 and a 52-week high of $4.09.
Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.67) EPS for the quarter, missing the consensus estimate of $0.15 by ($1.82). The business had revenue of $32.20 million for the quarter, compared to the consensus estimate of $58.10 million.
Several equities research analysts recently weighed in on NVLN shares. Zacks Investment Research cut shares of HENGAN INTL GRP/ADR from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 21st. ValuEngine upgraded shares of Westpac Banking from a “sell” rating to a “hold” rating in a research report on Wednesday, May 22nd.
Novelion Therapeutics Company Profile
Novelion Therapeutics Inc, a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand.
Further Reading: Terms to Better Understand Call Options
Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.